Insights

Centering discussion on patient profiles, expert panelists review recent advances in the treatment of renal cell carcinoma and their impact on clinical practice.

This OncLive Insights features a medical oncologist and gynecologic oncologist who share their thoughts on the selection of first-line and subsequent therapy in advanced endometrial cancer. They discuss treatment strategies and novel therapeutics that may improve health outcomes in patients with the disease.

Expert gynecologic oncologists provide a discussion on the care of patients with endometrial carcinoma.

Insight regarding the utilization of antibody-drug conjugate therapy to treat relapsed/refractory advanced bladder cancer.

Nicole Lamanna, MD, and Nirav N. Shah, MD, discuss the use of BTK inhibitors as targeted therapy for chronic lymphocytic leukemia and recent advancements.

This OncLive Insights features three immune thrombocytopenia experts who share their approach to treating different patient populations, considerations when selecting treatments, and emerging therapies for this condition.

Recommendations for assessing and treating patients with relapsed/refractory B-cell ALL based on more recent data presented at ASH 2021.

Expert oncologists navigate the evolving treatment landscape of advanced or metastatic urothelial carcinoma.

An overview of the role of currently-available and emerging BCMA-targeting therapies in the treatment landscape for multiple myeloma.

David Gerber, MD, and Steven Vernino, PhD, provide a discussion on Lambert-Eaton Myasthenic Syndrome (LEMS), its association with small cell lung cancer, and the available treatment options.

Experts come together to share their perspective on the paradigm of previously treated Ph+ chronic myeloid leukemia.

Approaches to planning treatment for patients with newly diagnosed chronic lymphocytic leukemia, as recommended by healthcare professionals from Memorial Sloan Kettering Cancer Center.

Discussion of recent clinical trial updates in HER2-positive metastatic breast cancer and implications for managing 2 patient case scenarios.

Experts in gastrointestinal cancers review optimal treatment strategies for the management of metastatic colorectal cancer (mCRC).

Expert hematologists provide insight on updates on the role of PI3K inhibitors in the treatment of relapsed/refractory MZL and FL.

Drs Arlene O. Siefker-Radtke and Scott T. Tagawa comment on opportunities for treating metastatic urothelial cancer with FGFR targeted therapies based on current trends in molecular testing and emerging therapies.

Practical perspectives on recent data and FDA approvals supporting novel agents that target EGFR exon 20 insertion mutations in non–small cell lung cancer.

Recommendations for managing HR-positive, HER2-negative metastatic breast cancer with CDK4/6 inhibitors and endocrine therapy.

This OncLive Insights features 3 experts who share their thoughts on how the treatment landscape of advanced NSCLC is evolving through use of comprehensive genetic sequencing to identify actionable biomarkers. They summarize how novel therapeutics which target driver alterations in ALK, ROS, RET, or NTRK can be leveraged to personalize and optimize management of advanced NSCLC, ultimately improving survival outcomes.